IGF-1 LR3

IGF-1 LR3 is a lab-made, longer-lasting version of a natural body chemical called insulin-like growth factor 1 (IGF-1). You’ll see it sold all over the place “for research use only,” and it’s often pitched as a muscle-builder. But the human proof for that muscle claim simply isn’t there.

What it is

Your body makes natural IGF-1, a hormone built from 70 amino acids (the small building blocks that make up proteins). It’s produced mostly in the liver when growth hormone tells it to. IGF-1 LR3 (“Long R3”) is a tweaked version with 83 amino acids. Two things were changed: one building block at position 3 was swapped out (arginine put in place of glutamic acid), and a string of 13 extra building blocks was tacked onto one end (the N-terminus, the “front” of the protein).

Why bother with those changes? They make the molecule much less likely to grab onto IGF binding proteins (IGFBPs) — the carrier proteins that normally latch onto most IGF-1 and keep it switched off. With less of that grabbing happening, IGF-1 LR3 stays loose and active far longer than the natural hormone (hours instead of minutes), and it packs more punch per dose in the lab.

Worth knowing: LR3 was never designed as a human medicine. It was invented as a cell-culture supplement — something added to vats of cells in factories to help them grow and pump out more protein. That’s still its main legitimate, regulated job today.

The claims

The marketing says IGF-1 LR3 builds muscle (both bigger muscle fibers, called hypertrophy, and even more muscle fibers, called hyperplasia), speeds up recovery and fat loss, wakes up muscle satellite cells (repair cells that sit beside muscle fibers), and helps tissues heal and “anti-age.” Sellers usually talk about these as if they’re proven.

What the evidence actually shows

The basic biology is real. IGF-1 LR3 docks onto the IGF-1 receptor (a switch on the surface of cells) and turns on two well-known signaling chains — the PI3K/Akt and MAPK/ERK pathways — that tell cells to build protein and multiply. In dishes of cells and in rodents, both IGF-1 and LR3 reliably trigger growth, and LR3 hits harder than the natural hormone in those tests.

Here’s the catch: there are no controlled human trials of IGF-1 LR3 for muscle, performance, body composition, or recovery. None. The human IGF-1 research that does exist studied the natural recombinant form (a lab-grown copy called mecasermin), used in a few specific medical conditions — that’s a different molecule, tested in patients, not healthy people chasing fitness goals. And just because something works in animals doesn’t mean it works the same way in people. A longer-acting, less-regulated version like LR3 could behave differently, and less predictably, in a human body. As of 2026, the muscle-building case is built on guesswork and animal data, not on real human results.

Legal and regulatory status

IGF-1 LR3 is not approved by the FDA for people to use, and it is not a dietary supplement. The only FDA-approved IGF-1 product is mecasermin (brand name Increlex), a lab-grown copy of natural IGF-1 approved for the long-term treatment of stunted growth in children with severe primary IGF-1 deficiency (a rare condition where the body can’t make enough IGF-1 on its own). That’s a different molecule used for a completely different reason. IGF-1 LR3 itself is sold as a “research use only” chemical. That label only allows it to be sold legally for genuine lab research — it is not a stamp of approval for putting it in your body.

In sport, IGF-1 and its lookalikes are banned at all times, both in and out of competition, by the World Anti-Doping Agency. They fall under its category for peptide hormones, growth factors, and related substances (the S2 group). Athletes who get tested risk penalties if they use it.

Safety

There is no human safety data for IGF-1 LR3 specifically. The likely risks come straight from how it works. Because it acts a bit like insulin, it can cause hypoglycemia (blood sugar dropping too low). And because IGF-1 signaling tells cells to grow, there are real worries — at least on paper — that long-term use could feed tumor growth or make tissues grow too much. That risk hasn’t been measured for LR3 in humans, so the size of it is unknown. On top of that, anything bought outside the regulated supply chain carries its own problems: you can’t be sure of the purity, the actual dose, or whether it’s contaminated. None of this is medical advice.

Bottom line

IGF-1 LR3 has a believable mechanism and genuinely builds tissue in animals and cell cultures — but there are zero human trials backing up the uses it’s marketed for. It isn’t approved for people, it’s banned in sport, and its safety in humans is simply unknown. The hype runs way out ahead of the evidence.

Evidence grade: 3/10 · Animal only.

Sources

• IGF-1 and the World Anti-Doping Agency Prohibited List — USADA
• WADA Statement on the prohibited substance IGF-1 — World Anti-Doping Agency
• INCRELEX (mecasermin) injection — FDA prescribing information
• Increlex (mecasermin) FDA Approval History — Drugs.com
• LONG R3 IGF-I Cell Culture Supplement — Repligen
• SAFC Biosciences Launches LONG R3 IGF-I as a Critical Raw Material for Industrial Cell Culture — BioSpace